The Molecular Basis for the Aberrant Production of Plasminogen Activator Inhibitor Type 2 in THP-1 Monocytes

Summary

Plasminogen activator inhibitor type 2 (PAI-2) is a urokinase inhibitor that is expressed primarily in monocytes. THP-1 monocytes, however, contain a unique defect in the production of PAI-2 in that the PAI-2 transcript is truncated and the expressed protein inactive (1). Here we describe the basis of this mutation in THP-1 cells. Southern blot analysis of THP-1-derived genomic DNA indicated that there were no obvious deletions in the structure of the PAI-2 gene. However, assessment of the THP-1-derived PAI-2 transcript by RT-PCR indicated that only exons seven and eight of the normal PAI-2 mRNA could be detected. Cloning of the 5’ region of the PAI-2 mRNA by 5-’RACE indicated that the PAI-2 cDNA derived from THP-1 cells is approximately 1329 bp long and contains 180 bp of sequence derived from intron 5, followed by sequences corresponding to exons seven and eight of the normal PAI-2 mRNA. The presence of the intron five fragment in endogenous THP-1 derived PAI-2 mRNA was confirmed by Northern blotting. The absence of any wild-type PAI-2 mRNA in these cells suggests that one copy of the PAI-2 allele has been deleted. The remaining allele producing the truncated mRNA appears to have undergone a translocation event and contains a mutation that has disrupted the splicing of the PAI-2 primary transcript.

Key words

PAI-2 - THP-1 monocytes - plasminogen activation

• References

• 1 Gross TJ, Sitrin RG. The THP-1 cell line is a urokinase-secreting mononuclear phagocyte with a novel defect in the production of plasminogen activator inhibitor-2. J Immunol 1990; 144: 1873-9.
• 2 Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997; 72: 1-22.
• 3 Vassalli JD. The urokinase receptor. 1994; Fibrinolysis 08 (Suppl. 01) 172-81.
• 4 Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-24.
• 5 Pytel PA, Peppel K, Baglioni C. Plasminogen activator inhibitor type-2 is a major protein induced in human fibroblasts and SK-MEL-109 melanoma cells by tumour necrosis factor. J Cell Physiol 1990; 144: 416-22.
• 6 Medcalf RL, Kruithof EKO, Schleuning W-D. Plasminogen activator inhibitor 1 and 2 are Tumor Necrosis Factor/Cachectin responsive genes. J Exp Med 1988; 168: 751-9.
• 7 Schwartz BS, Bradshaw JD. Regulation of plasminogen activator inhibitor mRNA levels in lipopolysaccharide-stimulated human monocytes. J Biol Chem 1992; 267: 7089-94.
• 8 Schleuning W-D, Medcalf RL, Hession C, Rothenbühler R, Kruithof EKO. Plasminogen activator inhibitor 2: Regulation of gene transcription in phorbol ester mediated differentiation of U-937 human histiocytic lymphoma cells. Mol Cell Biol 1987; 07: 4564-7.
• 9 Jensen PJ, Wu Q, Janowitz P, Ando Y, Schechter NM. Plasminogen activator inhibitor type 2: An intracellular keratinocyte differentiation product that is incorporated into the cornified envelope. Exp Cell Res 1995; 217: 65-71.
• 10 Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer 1994; 69: 398-405.
• 11 Foekens JA, Buessecker F, Peters HA, Krainick U, Vanputten WLJ, Look MP, Klijn JGM, Kramer MD. Plasminogen activator inhibitor-2- Prognostic relevance on 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423-7.
• 12 Ragno P, Montuori N, Vassalli J-D, Rossi G. Processing of complex between urokinase and its type-2 inhibitor on the cell surface. A possible regulatory mechanism for urokinase activity. FEBS Lett 1993; 323: 279-84.
• 13 Mahony D, Stringer BW, Dickinson JL, Antalis TM. DNase 1 hypersensitivity sites in the 5’ flanking region of the human plasminogen activator inhibitor type 2 (PAI-2) gene are associated with basal and tumor necrosis factor-α - induced transcription in monocytes. Eur J Biochem 1998; 256: 550-9.
• 14 Medcalf RL. Cell- and gene-specific interactions between signal transduction pathways revealed by okadaic acid: Studies on the plasminogen activating system. .J Biol Chem 1992; 267: 12220-6.
• 15 Sambrook J, Fritsch EF, Maniatis T. In: Molecular cloning: A Laboratory Manual. 2nd Ed.,. Cold Spring Harbour Laboratory; Cold Spring Harbour, NY: 1989
• 16 Cousin E, Medcalf RL, Bergonzelli GE, Kruithof EKO. Regulatory elements involved in constitutive and phorbol ester-inducible expression of the plasminogen activator type 2 gene promoter. Nucleic Acids Res 1991; 19: 3881-6.
• 17 Samia JA, Alexander SJ, Horten KW, Auron PE, Byers MG, Shows TB, Webb AC. Chromosomal organisation and localisation of the human urokinase inhibitor gene: perfect structural conservation with ovalbumin. Genomics 1990; 06: 159-67.
• 18 Silverman GA, Jockel JI, Domer PH, Mohr RM, Taillon-Millar P, Korsmeyer S. Yeast artificial chromosome cloning of a two megabase size contig within chromosome 18q21 establishes physical linkage between BCL2 and plasminogen activator inhibitor type 2. Genomics 1991; 09: 219-28.